Trial Profile

PLUTO: a Pilot Phase II Study of Perioperative TORIPALIMAB Plus LENVATINIB in Patients with Renal Cell Carcinoma Undergoing Nephrectomy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary) ; Lenvatinib (Primary) ; Sunitinib (Primary) ; Toripalimab (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms PLUTO

Most Recent Events

27 Feb 2025 Sequential assignment has been amended. 2) Planned number of patients has been changed from 32 to 54. 3) Trial identifier has been changed from 2022NZKY002-01 to 2025DZKY005-02. 4) Age criteria has been changed to 18-80 years old. 5)
27 Feb 2025 Planned number of patients changed from 32 to 54.
27 Feb 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com